A panel discussion during the eyeforpharma Virtual Conference discussed how the pandemic might impact the value of innovation, productivity and preparedness.
National Pharmaceutical Council (NPC) CSO Robert Dubois moderated the discussion, which featured Biogen Senior Vice President of Value and Access Chris Leibman and ICER Executive Vice President and COO Sarah Emond.
“Are Americans going to remember when this is over how important innovation is?” said Leibman. “Will we remember that you can’t just have thousands of people working on vaccines if there wasn’t already a paid-for infrastructure to do it?”
To read NPC’s blog post on the panel, click here.